Back to Stocks

IBRX

ImmunityBio, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

ImmunityBio is demonstrating a powerful commercial inflection point, highlighted by a 168% year-over-year surge in product revenue to $44.2 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the revenue growth, ImmunityBio remains burdened by a massive liability tower totaling approximately $1.5 billion, comprising convertible notes, revenue interest liabilities, and contingent value rights.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every IBRX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a crossroads between explosive commercial potential and precarious financial structuring. The rapid adoption of ANKTIVA and the removal of reimbursement hurdles provide a clear path toward the $1 billion revenue milestone, yet this path is narrow due to the seniority of its debt obligations. Investors are essentially betting on the velocity of the commercial rollout outstripping the decay of the cash pile. The synthesis of the data suggests that while the 'ghost' losses from fair value adjustments are accounting noise, the underlying debt service and operational burn are real. The critical metric for the next several quarters will be whether the J-Code unlock translates into a sustainable cash-flow positive trajectory before the $380.9 million in liquidity is exhausted or further diluted by warrant exercises.

Selected Quarter

Core Takeaway

ImmunityBio is successfully scaling ANKTIVA, but the financial upside is heavily leveraged against senior debt and founder-controlled liabilities.

Investor Lens

The trade-off is between the potential for a massive commercial re-rating and the risk of a liquidity crunch driven by senior debt service.

Watch Next

The 2026 sBLA submission for papillary disease and quarterly cash burn rates.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.29Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%
bullishMay 7

Product revenue surged 168% year-over-year to $44.2 million.

earnings beat
90%
bullishMay 7

Achieved a near-perfect gross margin of 99.5% on product sales.

margin expansion
95%
bearishMay 7

Company carries a massive $1.5B liability tower including senior revenue interests.

debt restructure
70%
neutralMay 7

Increased liquidity to $380.9M through ATM offerings and warrant exercises.

capital raise
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a crossroads between explosive commercial potential and precarious financial structuring. The rapid adoption of ANKTIVA and the removal of reimbursement hurdles provide a clear path toward the $1 billion revenue milestone, yet this path is narrow due to the seniority of its debt obligations. Investors are essentially betting on the velocity of the commercial rollout outstripping the decay of the cash pile. The synthesis of the data suggests that while the 'ghost' losses from fair value adjustments are accounting noise, the underlying debt service and operational burn are real. The critical metric for the next several quarters will be whether the J-Code unlock translates into a sustainable cash-flow positive trajectory before the $380.9 million in liquidity is exhausted or further diluted by warrant exercises.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.